Loading viewer...
investor_presentation
Format: PDF investor_presentation
Fusion Pharmaceuticals, a clinical-stage biotech company, presents its pipeline progress including Phase 1 trials for FPI-2059, acquisition of a Phase 2 PSMA-targeted prostate cancer program, and collaboration advances with AstraZeneca. The company highlights strategic supply agreements for actinium-225, a key therapeutic component in its targeted radiopharmaceutical platform.
26 Pages
Petros Pharmaceuticals